{"id":"W4405050900","doi":"10.1016/j.esmoop.2024.104073","title":"Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"National Cancer Institute; Ono Pharmaceutical; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Renal cell carcinoma; Open label; Internal medicine; Oncology; Randomized controlled trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007428909,0.000566307,0.001108447,0.0001084611,0.0007892863,0.0006235193,0.0007709864,0.0002102328,0.0001598105],"category_scores_gemma":[0.0003243002,0.0003622962,0.0001502425,0.0003220761,0.0001648659,0.0008465771,0.0007638974,0.0005585123,0.00004529036],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000972998,"about_ca_system_score_gemma":0.001164378,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004391379,"about_ca_topic_score_gemma":0.0004136317,"domain_scores_codex":[0.9962931,0.0002172481,0.0008937715,0.001355173,0.0006243407,0.0006163531],"domain_scores_gemma":[0.9966484,0.00126307,0.0003486818,0.001147254,0.0002490533,0.0003435761],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.959418,0.00235714,0.0001416975,0.00007753447,0.0005103807,0.0002403368,0.001541499,0.00002192113,0.0001852723,0.00005222129,0.01844792,0.01700607],"study_design_scores_gemma":[0.9298271,0.02269487,0.001425438,0.0004047311,0.001370804,0.00002444378,0.0003133609,0.001693487,0.001327312,0.0001453674,0.04029245,0.000480642],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9693899,0.001409943,0.0001533388,0.001371518,0.0007639303,0.01713895,0.0008783841,0.00008716913,0.008806896],"genre_scores_gemma":[0.9834637,0.00007455855,0.003253448,0.0002434742,0.0004342443,0.001612256,0.002144851,0.0001386333,0.008634825],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02959091,"threshold_uncertainty_score":0.9998829,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03543818598914407,"score_gpt":0.3104221155019698,"score_spread":0.2749839295128257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}